Submit Deal

MYOKARDIA

HQ - Brisbane

Summary

MyoKardia operates as a precision cardiovascular medicine company. The Company develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia serves patients in the United States.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 10.01 B

Avg. Deal Size£ 10.01 B

Market Context

Senior Management

Tassos Gianakakos
CEO
Taylor Harris
CFO
Michelle Corral
Investors Relations Director

Sort

05 Oct 2020|United States|Biotechnology

Target: MYOKARDIA

Bidder: BRISTOL MYERS SQUIBB COMPANY

13 Service Providers

7 Target | 6 Bidder

54 Dealmakers

32 Target | 22 Bidder

£ 10.01 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy